Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.54 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.49 |
| ▸ | CASP1 | P29466 | 3/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.49 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | ELANE | P08246 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4844148 | 0.85 | CTSL (0.47) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL3221956 | 0.83 | CTSL (0.52) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL7373971 | 0.83 | CTSL (0.52) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL2580714 | 0.83 | CTSL (0.52) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL3221965 | 0.83 | CTSL (0.52) | CTSLCTSSCTSBCTSKSYK | |
| SCHEMBL19827398 | 0.83 | CTSL (0.56) | CASP3CTSLCTSSCTSBCASP1 | |
| SCHEMBL2978398 | 0.82 | CTSL (0.63) | CASP3CTSLCTSSCTSBCASP1 | |
| SCHEMBL1287168 | 0.82 | CTSL (0.63) | CASP3CTSLCTSSCTSBCASP1 | |
| SCHEMBL8671882 | 0.82 | CTSL (0.63) | CASP3CTSLCTSSCTSBCASP1 | |
| SCHEMBL220569 | 0.82 | CTSL (0.63) | CASP3CTSLCTSSCTSBCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681871-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | Azevan Pharmaceuticals, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| WO-2019055913-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| EP-1434763-B1 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | AZEVAN PHARMACEUTICALS INC (US) | 2018-01-17 | — | — | EP | disclosed |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| US-20080090797-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | KOPPEL GARY A | 2008-02-07 | — | — | US | disclosed |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-28 | — | — | US | disclosed |
| WO-2005035492-A1 | 3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | SERENIX PHARMACEUTICALS, LLC. (US) | 2005-04-21 | — | — | WO | disclosed |
| US-20040266750-A1 | Beta-lactamyl vasopressin v1aantagonists | AZEVAN PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
| EP-1434763-A2 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | Serenix Pharmaceuticals, LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031407-A2 | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS | SERENIX PHARMACEUTICALS, LLC (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090797-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | CASP3 3633/4885CTSL 2379/4885CTSS 4254/4885 |
| US-20060217364-A1 | Beta-lactamyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | CASP3 4056/4885CTSL 1804/4885CTSS 2905/4885 |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | CASP3 3633/4885CTSL 2379/4885CTSS 4254/4885 |
| US-20080033165-A1 | [Beta]-Lactamyl Vasopressin V1a Antagonists and Methods of Use | AVPR2, AVPR1A, AVPR1B | CASP3 4353/4885CTSL 1304/4885CTSS 2338/4885 |
| US-20040266750-A1 | Beta-lactamyl vasopressin v1aantagonists | AVPR1A, AVPR2, AVPR1B | CASP3 4031/4885CTSL 2246/4885CTSS 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.